Call Us : +41 22 738 18 48

New targeted therapies for genetically linked skin diseases

Tuberous Sclerosis

  • Topical Rapamycin could be used to treat facial angiofibromas (“Adenoma Sebaceum”) (link) (Archives of Dermatology, 2010)

 

 

Neurofibromatosis (Recklinghausen’s Disease)

  • Mast cells play an important role
  • The c-Kit receptor on mast cells is stimulated by mediators that are liberated by Schwann cells
  • The activation of mast cells then induces the liberation of maediators that lead to proliferation of Schwann cells and the subsequent tumor formation.
  • Imatinib inhibits c-Kit activation and could therefore play a role

 

 

Basal Cell Carcinoma (BCC)

  • In Gorlin’s Syndrome as well as sporadic BCCs, mutations of the PTCH (Patched) gene have been found.
  • This mutations leads to the overactivity of the hedgehog pathway and subsequent carcinoma formation.
  • Inhibition of this pathway through inhibition of SMO (Smoothened) is possible with oral and topical substances (LDE 225 is an example…)

 

 

Progeria

  • Mutations of the LMNA gene have been found
  • Inhibition of the nuclear activation is possible with inhibitors of farnexytransferase

 

 

Recessive Dystrophic Epidermolysis Bullosa (EB)

  • deficiency of collagen VII is responsible for this condition.
  • It has been shown that injection of collagen VII into the wounds can reverse this phenomenon
  • When applied topically, it has been shown to accelerate wound healing in mice.

 

 

CHILD syndrome (Congenital Hemidysplasia with Ichtyosiform Lesions and Limb Defects)

  • Proteolysis of HMG Co-A is dependant on cholesterol. A lack of this leads subsequently to an abnormal Stratum Corneum.
  • Topical formulations containing 2% lovastatin and 2% cholesterol have been shown to show good clinical results (link)

 

 

Epidermolysis Bullosa Simplex (EBS)

  • Symptoms are due to a mutation and functional absence of keratin 14 (K14)
  • Addition of K16 can compensate for this loss.
  • Sulforaphane in Broccoli Sprouts could compensate for this loss by supplying K16 and K17.

 

 

Source of Information: SY 22. Paller A. Update on Genetic Disorders. 2012 (06) – 9th Spring Symposium of the EADV (European Academy of Dermatology and Venerology) – Verona, Italiy (Italia)

Original article: here